Related references
Note: Only part of the references are listed.Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
G. Fuca et al.
ESMO OPEN (2021)
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents
Hikmat H. Assi et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes
Eyyad Nassar et al.
CANCERS (2021)
Characterization of Organ-Specific Regulatory B Cells Using Single-Cell RNA Sequencing
Si-Yu Yang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R. Kelly et al.
LANCET HAEMATOLOGY (2021)
pH-responsive antibodies for therapeutic applications
Tomasz Klaus et al.
JOURNAL OF BIOMEDICAL SCIENCE (2021)
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A. Autio et al.
CLINICAL CANCER RESEARCH (2020)
The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation
Xidong Chen et al.
ONCOLOGY LETTERS (2020)
Sulfated syndecan 1 is critical to preventing cellular senescence by modulating fibroblast growth factor receptor endocytosis
Donghee Kang et al.
FASEB JOURNAL (2020)
Syndecan-1 andKRASGene Expression Signature Associates With Patient Survival in Pancreatic Cancer
Yixing Wu et al.
PANCREAS (2020)
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
Futa Mimoto et al.
CELL REPORTS (2020)
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu et al.
BLOOD CANCER JOURNAL (2020)
Proteoglycans remodeling in cancer: Underlying molecular mechanisms
Achilleas D. Theocharis et al.
MATRIX BIOLOGY (2019)
Soluble syndecans: biomarkers for diseases and therapeutic options
Jessica Bertrand et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
The role of syndecan-1 during endometrial carcinoma progression
Ozgen Arslan Solmaz
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2019)
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Wantong Yao et al.
NATURE (2019)
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
Chuang Sun et al.
Oncotarget (2019)
Structures and interactions of syndecans
Frank Gondelaud et al.
FEBS JOURNAL (2019)
Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1).
Jooeun Bae et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages
Marco Orecchioni et al.
FRONTIERS IN IMMUNOLOGY (2019)
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
Paola Orecchia et al.
CANCERS (2019)
PDZ Domains as Drug Targets
Nikolaj R. Christensen et al.
ADVANCED THERAPEUTICS (2019)
Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes
Tanyalak Parimon et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats
Heba A. Metwaly et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2018)
Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities
Solomon A. Agere et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Syndecan transmembrane domain modulates intracellular signaling by regulating the oligomeric status of the cytoplasmic domain
Bohee Jang et al.
CELLULAR SIGNALLING (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma
Tengteng Yu et al.
BLOOD (2018)
Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases
Colleen Chute et al.
BREAST CANCER RESEARCH (2018)
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Kurt Schoenfeld et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Sherif Abdelaziz Ibrahim et al.
MOLECULAR CANCER (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
DeannaLee M. Beauvais et al.
CANCER RESEARCH (2016)
Minireview: Syndecans and their crucial roles during tissue regeneration
Heesung Chung et al.
FEBS LETTERS (2016)
Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
Dan Chen et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Tiam1/Rac1 complex controls Il17a transcription and autoimmunity
Ahmed T. Kurdi et al.
NATURE COMMUNICATIONS (2016)
Syndecan-1-Induced ECM Fiber Alignment Requires Integrin αvβ3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains
Ning Yang et al.
PLOS ONE (2016)
Soluble Syndecan-1: Does This Biomarker Address a Seemingly Insoluble Problem in Inflammatory Bowel Disease?
Angela M. Patterson
DIGESTIVE DISEASES AND SCIENCES (2015)
A Unique Phenylalanine in the Transmembrane Domain Strengthens Homodimerization of the Syndecan-2 Transmembrane Domain and Functionally Regulates Syndecan-2
Mi-Jung Kwon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Mohamed R. Akl et al.
ONCOTARGET (2015)
Syndecan-1 and Its Expanding List of Contacts
Mary Ann Stepp et al.
ADVANCES IN WOUND CARE (2015)
Cell communication using intrinsically disordered proteins: what can syndecans say?
Elena I. Leonova et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2015)
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
J. Bae et al.
LEUKEMIA (2015)
Syndecans in angiogenesis and endothelial cell biology
Giulia De Rossi et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells
Sebastian W. Hofbauer et al.
BLOOD (2014)
Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer
Makito Miyake et al.
BMC CANCER (2014)
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
X. Wang et al.
BRITISH JOURNAL OF CANCER (2014)
Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non muscle-invasive bladder cancer
Joo Neon Kim et al.
HUMAN PATHOLOGY (2014)
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer
Tibor Szarvas et al.
HUMAN PATHOLOGY (2014)
Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang et al.
MOLECULAR ONCOLOGY (2014)
Syndecan-1 Overexpression Is Associated With Nonluminal Subtypes and Poor Prognosis in Advanced Breast Cancer
Thuy L. Nguyen et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
Jean-Charles Nault et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma
Paola Orecchia et al.
EUROPEAN JOURNAL OF CANCER (2013)
Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains
Tina Manon-Jensen et al.
FEBS JOURNAL (2013)
Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis
Alan C. Rapraeger et al.
FEBS JOURNAL (2013)
Molecular Mediators for Raft-dependent Endocytosis of Syndecan-1, a Highly Conserved, Multifunctional Receptor
Keyang Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+cells in poor outcome Hodgkin lymphoma patients
Rajendra Gharbaran et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Epithelial and stromal syndecan-1 and-2 are distinctly expressed in oral- and cutaneous squamous cell carcinomas
Abdirisak Ahmed Haji Omar et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2013)
Syndecans in cartilage breakdown and synovial inflammation
Thomas Pap et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Evaluation of BCL-6, CD10, CD 138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis
Khaldon Bodoori et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Heparan Sulfate Chains of Syndecan-1 Regulate Ectodomain Shedding
Vishnu C. Ramani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Function of the syndecan-4 cytoplasmic domain in oligomerization and association with α-actinin in turkey muscle satellite cells
Jonghyun Shin et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis
Yimin Xu et al.
MOLECULAR BIOLOGY REPORTS (2012)
Syndecan-syntenin-ALIX regulates the biogenesis of exosomes
Maria Francesca Baietti et al.
NATURE CELL BIOLOGY (2012)
Molecular functions of syndecan-1 in disease
Yvonne Hui-Fang Teng et al.
MATRIX BIOLOGY (2012)
The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol
Paul J. Barrett et al.
SCIENCE (2012)
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
Caroline Rousseau et al.
TUMOR BIOLOGY (2012)
Syndecan-1 in Breast Cancer Stroma Fibroblasts Regulates Extracellular Matrix Fiber Organization and Carcinoma Cell Motility
Ning Yang et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer
Rodrigo Ledezma et al.
ASIAN JOURNAL OF ANDROLOGY (2011)
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders
Jooeun Bae et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Role of Heparanase in Radiation-Enhanced Invasiveness of Pancreatic Carcinoma
Amichay Meirovitz et al.
CANCER RESEARCH (2011)
SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis
Joseph P. Ritchie et al.
CLINICAL CANCER RESEARCH (2011)
IMMUNOHISTOCHEMICAL STUDY IDENTIFYING PROGNOSTIC BIOMOLECULAR MARKERS IN NASOPHARYNGEAL CARCINOMA TREATED BY RADIOTHERAPY
Yeon-Joo Kim et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity
Vishnu C. Ramani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Prognostic significance of syndecan-1 expression in cervical cancers
Yu Im Kim et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2011)
Extracellular Matrix in Development: Insights from Mechanisms Conserved between Invertebrates and Vertebrates
Nicholas H. Brown
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis
Anurag Purushothaman et al.
BLOOD (2010)
PDZ domains and their binding partners: structure, specificity, and modification
Ho-Jin Lee et al.
CELL COMMUNICATION AND SIGNALING (2010)
Sdc1 negatively modulates carcinoma cell motility and invasion
Tohru Ishikawa et al.
EXPERIMENTAL CELL RESEARCH (2010)
Proteoglycans in health and disease: the multiple roles of syndecan shedding
Tina Manon-Jensen et al.
FEBS JOURNAL (2010)
Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation
DeannaLee M. Beauvais et al.
JOURNAL OF CELL SCIENCE (2010)
The Tiam1 PDZ Domain Couples to Syndecan1 and Promotes Cell-Matrix Adhesion
Tyson R. Shepherd et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression
Viktoriya Nikolova et al.
CARCINOGENESIS (2009)
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia
I. Jilani et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2009)
Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor
DeannaLee M. Beauvais et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Syndecan-1 and FGF-2, but Not FGF Receptor-1, Share a Common Transport Route and Co-Localize with Heparanase in the Nuclei of Mesenchymal Tumor Cells
Fang Zong et al.
PLOS ONE (2009)
Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors
Yosuke Hashimoto et al.
BMC CANCER (2008)
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
D. Loussouarn et al.
BRITISH JOURNAL OF CANCER (2008)
Membrane Type 1 Matrix Metalloproteinase-Mediated Stromal Syndecan-1 Shedding Stimulates Breast Carcinoma Cell Proliferation
Gui Su et al.
CANCER RESEARCH (2008)
Syndecan-1 expression in gallbladder cancer and its prognostic significance
Y. H. Roh et al.
EUROPEAN SURGICAL RESEARCH (2008)
Structural and Cell Adhesion Properties of Zebrafish Syndecan-4 Are Shared with Higher Vertebrates
James R. Whiteford et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma
Anurag Purushothaman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF
Andreas-Claudius Hoffmann et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy
Shahrokh F. Shariat et al.
BJU INTERNATIONAL (2008)
Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions
Ian C. Dews et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma
Karene Mahtouk et al.
BLOOD (2007)
Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation
Gui Su et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Interactions between heparan sulfate and proteins: the concept of specificity
Johan Kreuger et al.
JOURNAL OF CELL BIOLOGY (2006)
Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype
Fusun Baba et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Reduced syndecan-I expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma
H Kurokawa et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2006)
Syndecan-1 expression by stromal. broblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis
T Maeda et al.
ONCOGENE (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3
GB ten Dam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells
K Ding et al.
JOURNAL OF CELL BIOLOGY (2005)
Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site
ZH Wang et al.
BIOCHEMISTRY (2005)
Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival
R Lovell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling
K Forsten-Williams et al.
JOURNAL OF THEORETICAL BIOLOGY (2005)
Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer
Y Shinyo et al.
GYNECOLOGIC ONCOLOGY (2005)
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer
M Lundin et al.
ONCOLOGY (2005)
Syndecan-1 expression - A novel prognostic marker in pancreatic cancer
A Juuti et al.
ONCOLOGY (2005)
Altered expression of syndecan-1 in prostate cancer
J Kiviniemi et al.
APMIS (2004)
Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors - A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor
SS Deepa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells
DLM Beauvais et al.
JOURNAL OF CELL BIOLOGY (2004)
Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma
L Shah et al.
CANCER (2004)
Syndecan-1 transmembrane and extracellular domains have unique and distinct roles in cell spreading
KJ McQuade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration
K Endo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain
F Granés et al.
FEBS LETTERS (2003)
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in pro-state cancer
T Zellweger et al.
PROSTATE (2003)
Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury
QL Li et al.
CELL (2002)
Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific kill T cells dentritic cells
KM Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery
A Anttonen et al.
LUNG CANCER (2001)
Share Paper
